Stephen David Prior - 05 Jan 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Strategy Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Stephen David Prior
Issuer symbol: ANTX
Transactions as of: 05 Jan 2026
Net transactions value: -$6,507
Form type: 4
Filing time: 07 Jan 2026, 20:15:13 UTC
Previous filing: 06 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Prior Stephen David	Chief Strategy Officer	C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK	/s/ Lucy Day, Attorney-in-Fact for Stephen David Prior	07 Jan 2026	0002042268

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Sale	$3,615	-3,604	-5.5%	$1.00	61,944	05 Jan 2026	Direct	F1, F2
transaction	ANTX	Common Stock	Sale	$2,892	-2,858	-4.6%	$1.01	59,086	06 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
F2	Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

Content

Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.

Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.